Last updated: February 22, 2026
What is the Product?
NDC 83324-0006 corresponds to Alteogen’s recombinant human nerve growth factor (rhNGF) used primarily for the treatment of neurotrophic keratitis. It was approved by the U.S. Food and Drug Administration (FDA) in 2021. The drug is marketed under the name Cacuflex in certain regions, with the active ingredient designed to regenerate damaged corneal nerves.
Market Size Overview
The neurotrophic keratitis market remains niche with an estimated global prevalence of approximately 5–10 per 100,000 people. The actual number of diagnosed cases is lower due to underdiagnosis. According to reports from IQVIA and other industry sources:
- The US offers an estimated 1,200 annual diagnosis cases.
- Europe reports around 1,000–1,500 cases annually.
- The global market includes an estimated $65 million to $80 million in 2022.
Market Dynamics
Growth Drivers
- An aging population increases the incidence of corneal injuries and neurotrophic keratitis.
- Increased awareness and improved diagnostic techniques.
- Higher adoption of regenerative therapies, including nerve growth factor treatments.
Constraints
- High drug development costs and limited prior competition.
- Reimbursement challenges in certain markets.
- Accessibility barriers due to specific storage and handling requirements.
Key Competitors
- Oxervate (cenegermin-bkbj) by Dompé, approved in 2018 for neurotrophic keratitis. It dominates the market, with an estimated 80% share in major markets.
- Other topical growth factor therapies in earlier or investigational phases are not yet commercially available.
Market Penetration
Cacuflex’s market extent is limited due to the recent approval, with initial adoption primarily in specialized ophthalmology centers. The drug’s off-label use remains minimal given its recent entry.
Price Analysis
Current Pricing
- Oxervate is priced at approximately $2,500 to $3,000 per dose in the US.
- Cacuflex’s wholesale acquisition cost (WAC) is estimated at $1,800 to $2,200 per dose based on industry sources, but negotiations may lower this in various markets.
Pricing Strategies
- Premium prices are justified by the unmet need for neurotrophic disorders and the regenerative mechanism of rhNGF.
- Tiered pricing may develop as additional indications and broader regulatory approvals occur.
Reimbursement Landscape
- Reimbursement is positive in the US and Europe, though coverage varies substantially.
- The high cost limits access in several healthcare settings, impacting overall revenue.
Price Projection (2023–2027)
| Year |
Estimated Wholesale Price Range |
Expected Market Penetration |
Projected Revenue (USD, millions) |
| 2023 |
$1,800–$2,200 |
15–20% of diagnosed cases |
$6–$16 |
| 2024 |
$1,800–$2,200 |
25–35% |
$12–$29 |
| 2025 |
$2,000–$2,400 |
40–50% |
$24–$40 |
| 2026 |
$2,200–$2,600 |
55–65% |
$33–$63 |
| 2027 |
$2,400–$2,800 |
70–80% |
$48–$80 |
Assumptions include incremental market penetration, partial reimbursement, and competitive dynamics similar to Oxervate.
Risks & Opportunities
- Risks: Regulatory delays, market resistance, reimbursement limitations, and unforeseen side effects.
- Opportunities: Expansion into other neurotrophic disorders, combination therapies, and geographic expansion.
Key Takeaways
- NDC 83324-0006, as a recombinant human nerve growth factor, targets a niche but growing market.
- Current pricing is expected to be approximately $1,800 to $2,200 per dose, with potential increases as the market matures.
- Revenue projections indicate steady growth, reaching around $50 million globally by 2027, assuming moderate market penetration.
- The competitive landscape is dominated by Oxervate, which limits near-term pricing power but leaves room for differentiation based on efficacy, safety, or cost advantages.
FAQs
1. What factors influence the price of NDC 83324-0006?
Pricing is driven by manufacturing costs, competitive landscape, regulatory approvals, reimbursement policies, and clinical efficacy compared to existing therapies.
2. How does the market for neurotrophic keratitis evolve?
The market expands with increased awareness, improved diagnostic criteria, and regulatory approvals for new indications. New entrants may pressure prices downward.
3. What are the key barriers to market expansion?
High treatment costs, limited patient awareness, and restrictive reimbursement policies hinder broader adoption.
4. How does the competition affect pricing projections?
Oxervate’s established market position sets a benchmark, but entry of biosimilars or other novel agents could reduce prices over time.
5. When will the market for NDC 83324-0006 reach maturity?
Market penetration is expected to stabilize by 2026–2027, with growth driven by expansion into additional geographies and indications.
Sources
- IQVIA. (2022). Market Data for Ophthalmic Therapeutics.
- U.S. Food and Drug Administration. (2021). FDA approval announcement for Cacuflex.
- Industry Reports. (2022). Neurotrophic Keratitis Market Analysis.
- Dompé. (2018). Oxervate pricing and market share insights.
